US006331415C1
`(12) EX PARTE REEXAMINATION CERTIFICATE (6829th)
`United States Patent
`US 6,331,415 Cl
`(lo) Number:
`Cabilly et al.
`Certificate Issued:
`May 19, 2009
`
`IMMUNOGLOBULINS, VECTORS AND
`
`Herbert L. Heyneker, Burlingame, CA
`(US); William E. Holmes, Pacifica, CA
`(US); Arthur D. Riggs, La Verne, CA
`(US); Ronald B. Wetzel, San Francisco,
`CA (US)
`
`(73) Assignees: Genentech, Inc., South San Francisco,
`CA (US); City of Hope, Duarte, CA
`(US)
`
`Reexamination Request:
`No. 90/007,542, May 13, 2005
`No. 90/007,859, Dec. 23, 2005
`
`Reexamination Certificate for:
`Patent No.:
`6,331,415
`issued:
`Dec. 18, 2001
`Appl. No.:
`07/205,419
`Filed:
`Jun. 10, 1988
`
`Certificate of Correction issued Jun. 25, 2002.
`
`Related U.S. Application Data
`
`(63) Continuation of application No. 06/483,457, filed on Apr. 8,
`1983, now Pat. No. 4,816,567.
`
`(51)
`
`(52)
`
`C12N 15/13
`C12N 15/00
`C12N 15/63
`
`(2006.01)
`(2006.01)
`(2006.01)
`
`435/69.6; 435/252.1; 435/252.3;
`435/252.33; 435/254.11; 435/254.2; 435/254.21;
`435/69.7; 435/70.21; 435/71.2; 435/71.1;
`435/70.1; 435/320.1; 435/455; 435/483;
`435/485; 435/471; 435/69.1
`.......................... None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,224,404 A
`4,348,376 A
`4,366,246 A
`4,370,417 A
`4,399,216 A
`4,419,446 A
`4,431,740 A
`4,440,859 A
`4,500,637 A
`4,511,502 A
`4,565,785 A
`4,599,197 A
`4,634,665 A
`4,642,334 A
`4,668,629 A
`4,713,339 A
`4,766,075 A
`
`9/1980 Viza
`9/1982 Goldenberg
`12/1982 Riggs
`1/1983 Hung
`8/1983 Axel et al.
`12/1983 Howley
`2/1984 Bell
`4/1984 Rutter
`2/1985 Neville, Jr. et al.
`4/1985 Builder et al.
`1/1986 Gilbert
`7/1986 Wetzel
`1/1987 Axel et al.
`2/1987 Moore
`5/1987 Kaplan et al.
`12/1987 Levinson et al.
`8/1988 Goeddel et al.
`
`4,792,447 A
`4,816,567 A
`4,965,196 A
`5,081,235 A
`5,098,833 A
`5,116,964 A
`5,137,721 A
`5,179,017 A
`5,225,538 A
`5,336,603 A
`5,420,020 A
`5,428,130 A
`5,455,165 A
`5,500,362 A
`5,514,582 A
`5,561,053 A
`5,583,013 A
`5,585,089 A
`5,605,689 A
`5,612,185 A
`5,648,237 A
`5,686,072 A
`5,721,108 A
`5,736,137 A
`5,807,715 A
`5,840,545 A
`5,846,818 A
`5,877,293 A
`5,965,405 A
`5,997,867 A
`6,054,297 A
`6,054,561 A
`6,120,767 A
`6,204,023 B1
`6,331,415 B1
`6,455,275 B1
`6,548,640 B1
`
`12/1988 Uhr et al.
`3/1989 Cabilly et al.
`10/1990 Levinson et al.
`1/1992 Shively et al.
`3/1992 Lasky et al.
`5/1992 Capon et al.
`8/1992 Dallas
`1/1993 Axel et al.
`7/1993 Capon et al.
`8/1994 Capon et al.
`5/1995 Riggs
`6/1995 Capon et al.
`10/1995 Capon et al.
`3/1996 Robinson et al.
`5/1996 Capon et al.
`10/1996 Crowley
`12/1996 Itakura
`12/1996 Queen et al.
`2/1997 Ammann
`3/1997 Uhr et al.
`7/1997 Carter
`11/1997 Uhr et al.
`2/1998 Robinson et al.
`4/1998 Anderson et al.
`9/1998 Morrison et al.
`11/1998 Moore
`12/1998 Robinson et al.
`3/1999 Adair et al.
`10/1999 Winter
`12/1999 Waldmann et al.
`4/2000 Carter et al.
`4/2000 Ring
`9/2000 Robinson et al.
`3/2001 Robinson et al.
`12/2001 Cabilly et al.
`9/2002 Axel et al.
`4/2003 Winter
`
`EP
`EP
`EP
`
`FOREIGN PATENT DOCUMENTS
`
`0 036 776
`044722
`0 044 722
`
`3/1981
`1/1982
`1/1982
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`Harvard Journal of Law & Technology 17(2) (Spring 2004),
`pp. 583-618.*
`
`Appl. No. 08/461,071.*
`Declaration of Dr. Richard Axel, submitted Oct. 5, 1989 in
`U.S. Appl. No. 08/422,187.*
`
`(Continued)
`
`Primary Examiner—Padmashri Ponnaluri
`
`(57)
`
`ABSTRACT
`
`The invention relates to processes for producing an immuno-
`globulin or an immunologically functional immunoglobulin
`
`immunoglobulin heavy and light chains. The processes can
`use one or more vectors which produce both the heavy and
`light chains or fragments thereof in a single cell. The inven-
`tion also relates to the vectors used to produce the immuno-
`globulin or fragment, and to cells transformed with the vec-
`tors.
`
`Genzyme Ex. 1006, pg 101
`
`

`
`US 6,331,415 Cl
`Page 2
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`060057
`0 114 506
`102634
`0171496
`173494
`177343
`365997
`0481790
`81/02426
`WO 82/03088
`83/00164
`87/02671
`89/00999
`89/01783
`92/16553
`93/07899
`93/10817
`93/21319
`97/30087
`
`9/1982
`12/1983
`3/1984
`2/1986
`3/1986
`4/1986
`5/1990
`4/1992
`9/1981
`9/1982
`1/1983
`5/1987
`2/1989
`3/1989
`10/1992
`4/1993
`6/1993
`10/1993
`8/1997
`
`OTHER PUBLICATIONS
`
`Accolla et al., Proc. Nat'l A cad. Sci. USA 77:563 (1980).
`79:7862
`
`(1982).
`Deacon et al., Antibody Synthesis in Xenopus Oocytes with
`Messenger Ribonucleic Acid from Immunized Rats, Bio-
`chemical Society Transactions, vol. 4, pp. 818-820 (1976).
`Ochi et al., Transfer of a cloned immunoglobulin light—chain
`gene to mutant hybridoma cells restores specific antibody
`production, Nature, vol. 302, pp. 340342 (1983).
`Oi et al., lmmunoglobulin gene expression in transformed
`
`825-829 (1983).
`Rice et al., Regulated expression for an immunoglobulin
`gene introduced into a mouse lymphoid cell line, Proc. Natl.
`Acad. Sci. USA, vol. 79, pp. 7862-7865 (1982).
`Valle et al., Synthesis and secretion of mouse immunoglobu-
`
`338-340 (1981).
`Valle et al., Anti—ovalbumin monoclonal antibodies interact
`X enopus
`
`oocytes, Nature, vol. 300, pp. 71-74 (1982).
`U.S. Appl. No. 07/233,430, Boss et al.
`U.S. Appl. No. 07/930,821, Boss et al.
`U.S. Appl. No. 08/320,381, Boss et al.
`U.S. Appl. No. 08/450,727, Boss et al.
`U.S. Appl. No. 08/452,420, Boss et al.
`U.S. Appl. No. 08/453,449, Boss et al.
`Abbas et al., Cellular and Molecular Immunology, Second
`Edition pp. 38-39 (1994).
`Abstract, Journal of Nuclear Medicine, May 1990, No. 613
`(Exhibit 1177, lnt. No. 104,532).
`
`D.C., Tuesday, Jun. 19—Friday, Jun. 22, 1990 (Exhibit 1180,
`lnt. No. 104,532).
`Abstract, World Federation of Nuclear Medicine & Biology,
`
`104,532).
`Achord et al. 1978. Human 0—glucuronidase: in vivo clear-
`ance and in vitro uptake by a glycoprotein recognition sys-
`tem on reticuloendothelial cells. Cell 15:269-278.
`Alberts et al. Molecular Biology of The Cell, pp. 285 and
`375. Garland Publishing, lnc., (1983).
`
`Alberts, B. Molekularbiologie der Zelle, Weinheim: VCH p.
`1075 (1987).
`
`class switching in a murine leukaemia cell line," Nature, vol.
`298, p. 325-31, (Mar. 25, 1982).
`Andrews, D.W. and J.D. Capra. 1980. Clinical lmmunobiol-
`ogy. pp. 1-18, W.B. Sanders.
`Arathoon, et al. Large—Scale Cell Culture in Biotechnol-
`ogy pp. 1390-1395, Science, vol. 232, Jun. 1986 (Exhibit
`1157; lnt. No. 104,532).
`Arthritis & Rheumatism, Abstract Suppl. vol. 39, No. 9, Sep.
`1996, p. S244.
`Ashford et al. 1993 "Site—specific Glycosylation of Recom-
`binant Rat and Human Soluble CD4 Variants Expressed in
`
`3260-3267.
`Bagdasarian et al., "Activity of the hybrid trp—lac (tac) pro-
`moter of putida. Construction of broad—host—range, con-
`trolled—expression vectors" Gen 26 (2-3): 273-282 (Dec.
`1983).
`
`lmmunoconjugates. The Parthenon Publishing Group (UK),
`p. 209.
`Banerji et al., "A Lymphocyte—Specific Cellular Enhancer is
`Located Downstream of the Joining Region in lmmunoglo-
`
`1982).
`J. Baselga et al., "Recombinant Humanized Anti—HER2
`Antibody (HerceptinTM) Enhances the Antitumor Activity of
`Paclitaxel and Doxorubicin against HER2/neu Overexpress-
`ing Human Breast Cancer Xenografts", Cancer Res. (1988)
`58: 2825-2831.
`Beatty et al., Cancer Research (Suppl). 50:922s-926s (Feb.
`1, 1990) (Exhibit 1011; lnt. No. 104,532).
`
`1989) (Exhibit 1010; lnt. No. 104,532).
`Begent et al., Br. J. Cancer, 62:487 (1990) (Exhibit 1088; lnt.
`No. 104,532).
`
`SV40 early promoter region," Nature, 290: 304-310 (1981).
`Bergman, Y, et al., "Two regulatory elements for immuno-
`Proc. Natl.
`
`Acad. Sci., 81: 7041-45 (1984).
`Berman et al., Science, Nov. 4, 1983; 222(4623): 524-7.
`Bernier, "Proliferative Disorders of the immune System,"
`Chapter 21 (pp. 622-643) in Bellanti, Immunology 11(1978).
`Bindon et al. (1985). Therapeutic potential of monoclonal
`antibodies to the leukocyte—common antigen. Synergy and
`interference in complement—mediated lysis. Transplantation
`40(5):538-44 (Exhibit 2072; lnt. No. 104,532).
`
`tunicamycin on the secretion of 1gM and lgG produced by
`the same cells. European Journal Of Immunology 11:65-66.
`Blair, DG, et al., "Activation of the transforming potential of
`a normal cell sequence: a molecular model for oncogenesis,"
`Science, 212: 941-43 (1981).
`Breathnach, R., et al. "Corrected splicing of a chicken oval-
`bumin gene transcript in mouse L cells," Proc. Natl. Acad.
`Sci., 77: 740-44 (1980).
`Bruggemann et al. 1987. Comparison of the effector func-
`
`166(5):1351-61 (Exhibit 2079; lnt. No. 104,532).
`
`Genzyme Ex. 1006, pg 102
`
`

`
`US 6,331,415 Cl
`Page 3
`
`Byrn, et al., Nature 344:667-670 (Apr. 12, 1990) (Exhibit
`1055; Int. No. 104,532).
`
`scripts and molecular history of a hybridoma that produces
`antibody to carcinoembryonic antigen. Gene 40(I):157-61
`(Exhibit 2073; Int. No. 104,532).
`
`allows the production of functional, antigen—binding Fab
`fragments in Escherichia coli" Gene 85:553-57 (1989).
`Cancer Principles & Practice of Oncology, 5th Edition, vol.
`1, Chapter 18, pp. 360-372 (Exhibit 1181; Int. No. 104,532).
`Carter et al., "High Level Escherichia coli Expression and
`Production of a Bivalent Humanized Antibody Fragment."
`Bio/Technology 10(2):153-167 (Feb. 1992).
`
`repeat DNA," Science, 210: 1249-51 (1980).
`
`5640-5644 (1987) (Exhibit 1107; Int. No. 104,532).
`Clynes et al., 2000 "Inhibitory Fc receptors modulate in vivo
`cytoxicity against tumor antigens" Nature Med 6: 443-446.
`Cobbold et al., Bone Marrow Purging and Processing, pp.
`139-154 (Jan. 1, 1990) (Exhibit 1027; Int. No. 104,532).
`Cobbold, S.P. and H. Waldmann, "Therapeutic potential of
`monovalent
`308(5958):460-62 (1984) (Exhibit 2068; Int. No. 104,532).
`Code of Medical Ethics and Current Opinions, excerpts from
`pp. 339-379 (Exhibit 2269; Int. No. 104,532).
`Colcher et al., Cancer Res. 49:1738-1745 (1989) (Exhibit
`1047; Int. No. 104,532).
`Crowe, et al., A Clinical Experimental Immunology, 1992,
`87, pp. 105-110 (Exhibit 1070; Int. No. 104,532).
`Davies, J., et al., "A new selective agent for eukaryotic clon-
`ing vectors," Am J. Trop. Med. Hyg., 29 (5 Suppl): 1089-92
`(1980).
`Davis et al. 1990, "High Level Expression in Chinese Ham-
`ster Ovary Cells of Soluble Forms of CD4 T Lymphocyte
`
`Chem. 265, 10410-10418 (Exhibit 2189; Int. No. 104,532).
`Davis, "Immunoglobulin molecules and genes" Microbiol-
`ogy Including Immunology and Molecular Genetics, Third
`
`Hagerstown, MD.
`De Waele et al. 1988. Expression in non—tymphoid cells of
`mouse recombinant immunoglobulin directed against the
`tumor marker human placental alkaline phosphatase. Euro-
`pean Journal of Biochemistry 176:287-295 (Exhibit 2109;
`Int. No. 104,532).
`Dean, C.J. 1994. Preparation and characterization of mono-
`clonal antibodies to proteins and other cellular components.
`Methods in Molecular Biology 32:361-379 (Exhibit 2026;
`Int. No. 104,532).
`
`from the trp and lac Promoters" Proc. Natl. Acad. Sci. USA
`80:21-25 (1983).
`Devita et al., Cancer: Principles & Practice of Oncology,
`1997, 5th Ed., vol. 1, Chapter 18, VT. DeVita (Ed.), Lippin-
`cott—Raven, Philadelphia, PA.
`
`Estabrook A. and J. A. K. Patterson, "Immunotherapy using
`
`559-66 (1983).
`Ettinger, et al. Cancer Treatment Reports vol. 83, No. 1, pp.
`131-134, Jan. 1979 (Exhibit 1129; Int. No. 104,532).
`
`(Exhibit 1069; Int. No. 104,532).
`Fittler et al., "Localization in Mouse—L—Cell Chromosomal
`Sites of Transferred Immunoglobulin Genes," Chromosoma
`(Berl.) 84, 717-727 (1982).
`
`(Exhibit 1080 Case No. CIV S-00-1252 WBS GGH).
`Frenkel et al. 1980. Analysis and detection of B cell neo-
`plasms. Blood Cells 6:783-793 (Exhibit 2123; Int. No. 104,
`532).
`
`(Exhibit 1023; Int. No. 104,532).
`Fundenberg and Koistinen, "Human Allotype Detection by
`Passive Hemagglutination, with Special Reference to Immu-
`noglobulin A Allotypes" Chapter 103 (pp. 767-774) in Rose
`and Friedman, Manual of Clinical Immunology, Second Edi-
`tion (1980).
`Geisse et al. 1996. Eukaryotic expression systems: a com-
`
`(Exhibit 2025; Int. No. 104,532).
`Gillies et al., "Expression of cloned immunoglobulin genes
`introduced into mouse L cells," Nucl. Acids. Res., vol. 11,
`No. 22, pp. 7982-7997 (1983).
`Glaser et al., "Functional interrelationship between two tan-
`E.
`302(59031:74-76 (Mar. 3, 1983).
`Goeddel et al. 1979. Direct expression in Escherichia coli
`a DNA sequence coding for human growth hormone. Nature
`281(5732):544-8 (Exhibit 2038; Int. No. 104,532).
`Goeddel et al., "Synthesis of Human Fibroblast Interferon
`
`(1980).
`Goeddel, Methods in Enzymology, vol. 185, AGene Expres-
`sion Technology (1990) (Exhibit 1077; Int. No. 104,532).
`Gold et al. 1978. Carcinoembryonic antigen (CEA) in clini-
`cal medicine. Cancer 42:1399-1405 (Exhibit 2135; Int. No.
`104,532).
`Goochee et al. 1991, "The Oligosaccharides of Glycopro-
`teins: BioProcess Factors Affecting Oligosaccharide Struc-
`ture and Their Effect on Glycoprotein Properties", Bio Tech-
`nology 9, 1347-1355 (Exhibit 2187; Int. No. 104,532).
`Goochee, C. F., and T. Monica. 1990. Environmental effects
`
`(Exhibit 2023; Int. No. 104,532).
`
`from a mixture of cDNA molecules" Methods in Enzymol-
`ogy 68:75-90 (1979).
`Greipp, P. 1992. Advances in the diagnosis and management
`of myeloma. Seminars in Hematology 29(3: Suppl. 2):24-45
`(Exhibit 2020; Int. No. 104,532).
`Grillo—Lopez et al. 1999. Overview of the clinical develop-
`
`(Exhibit 1014; Int. No. 104,532).
`
`1025; Int. No. 104,532).
`
`3(3):241-251 (Exhibit 1087; Int. No. 104,532).
`
`Oncology 26:66-73 (Exhibit 2144; Int. No. 104,532).
`Gross et al, "Bone marrow Purging and Processing," Interna-
`tional Symposium on Bone Marrow Purging and Processing
`(2nd, Apr. 27 and 28, 1989 Cancun, Mexico) Gross et al.
`(Ed.), Wiley—Liss, NY.
`
`Genzyme Ex. 1006, pg 103
`
`

`
`US 6,331,415 Cl
`Page 4
`
`Grossbard, M.L. 1998. Monoclonal Antibody Based
`Therapy of Cancer. Marcel Dekker, p. 451 (Exhibit 2094;
`Int. No. 104,532).
`Gruss, P., et al., "Simian virus 40 tandem repeated sequences
`as an element of the early promoter," Proc. Natl. A cad. Sci.,
`78:943-47 (1981).
`Habara et al. "Rauscher Murine Leukemia Virus: Molecular
`Cloning of Infectious Integrated Proviral DNA," J. of Virol-
`ogy, vol. 44, No. 2, pp. 731-735 (No.v 1982).
`Hale et al. 1985. Reactivity of rat monoclonal antibody
`CAMPATH—I with human leukemia cells and its possible
`application for autologous bone marrow transplantation.
`British Journal of Hematology 60(I):41-8 (Exhibit 2074;
`Int. No. 104,532).
`Hale et al. 1988. Remission induction in non Hodgkin lym-
`phoma with reshaped human monoclonal antibody CAM-
`PATH—I H. Lancet 2 (8625): 1394-1399 (Exhibit 2015 and
`1024; Int. No. 104,532).
`Hale et al., 1990. The Campath—I antigen (CDw52). Tissue
`Antigens 35:118-127 (Exhibit 2049 Int. No. 104,532).
`Hale, "Effects of Monoclonal Anti—lymphocyte Antibodies
`in Vivo in Monkeys and Humans", Mol Biol Med (1983) 1,
`321-334 (Exhibit 2240; Int. No. 104,532).
`Hale, Progress Report (May 1990—Dec. 31, 1990), MRC
`Wellcome Therapeutic Antibody Center (Exhibit 1072; Int.
`No. 104,532).
`Hamilton, R., "Application of engineered chimeric antibod-
`ies to the calibration of human antibody standards" Annales
`de Biologie Clinigue 49 (4):242-248 (1991).
`Harris "Expression of Eukaryotic Genes in E. coli" Genetic
`Engineering, R.Williamson, 4 th edition pp. 127-185 (1983).
`Harris, et al., Proceedings of the 34th Oholo Conference,
`Eilat, Israel (1990) (Exhibit 1073; Int. No. 104,532).
`Haynes and Weissmann, "Constitutive, long—term produc-
`tion of human interferons by hamster cells containing mul-
`tiple copies of a cloned interferon gene," (1983) Nucl. Acid.
`Res., vol. 11 No. 3, pp. 687-706 (Exhibit 1109; Int. No.
`104,532).
`Hodge, J.W. 1996. carcinoembryonic antigen as a target for
`cancer vaccines. Cancer Immunol and Immunother
`43:127-134 (Exhbit 2032; Int. No. 104,532).
`Hutchins et al., Proc. Natl. Acad. Sci. USA, vol. 92, pp.
`11980-11984 (1995).
`Huynh et al., 1984. Constructing and screening cDNA
`libraries in kgt I0 and kgtl 1. DNA Cloning, vol. I A prac-
`tical Approach 49-78. Glover, D(Editor), IRL Press, Oxford
`(Exhibit 2050; Int. No. 104,532).
`Jackson and Davis, "Quantitation of Immunoglobulins,"
`Chapter 14 (pp. 109-120) in Rose and Friedman,
`Clinical Immunology, Second Edition (1980).
`Jefferis et al. 1998. IgG—Fc—mediated effector functions:
`molecular definition of interaction sites for effector ligands
`and the role of glycosylation Immunological Reviews
`163:59-76 (Exhibit 2095; Int. No. 104,532).
`Joziasse, et al., 2000 "a3—Galactosylated glycoproteins can
`bind to the hepaticasialoglycoprotein receptor" Eur. J. Bio-
`chem. 267:6501-6508 (Exhibit 1037; Int. No. 104,532).
`Kabat et al. Sequences of Proteins of Immunological Inter-
`est, Bethesda, MD: National Institute of Health pp. i, xxi,
`xxii (1983).
`Khazaeli, et al., Cancer Research, 51, 5461-5466 (1991)
`(Exhibit 1074; Int. No. 104,532).
`
`Kabat et al., "Sequences of immunoglobulin chains: tabula-
`
`precursors, V—regions, C—regions, J—chain and [beta]2—
`microglobulins . . . ," The Kabat Database of Sequences of
`Proteins of Immunological Interest, 1979, Publication No.
`80-2008, p. 185, National Institute of Health, Bethesda,
`MD. (GNE—MED 52680).
`Kaetzel et al. 1985. Expression of biologically active bovine
`luteinizing hormone in Chinese hamster ovary cells. Proc.
`Natl. Acad Sci. USA 82:7280-7283 (Exhibit 2152; Int. No.
`104,532).
`Kagawa Y; J Biol Chem Nov. 25, 1988:263(33):17508-15
`(Exhibit 1153; Int. No. 104,532).
`Kaufman et al. 1987. Coamplification and coexpression of
`human tissue—type plasminogen activator and murine dihy-
`drofolate reductase sequences in Chinese hamster ovary
`cells. Molecular and Cellular Biology 5:1750-1759 (Exhibit
`2075; Int. No. 104,532).
`Khazaeli et al., Manuscript Frequent Anti—V Region
`Immune Response to Mouse B72.3 Monoclonal Antibody
`(pp. 25-63).
`Kipriyanov et al. 1999. Generation of recombinant antibod-
`ies. Molecular Biotechnology 12:173-201 (Exhibit 2017;
`Int. No. 104,532).
`Klausner, A. "Genentech makes monoclonal precursors
`from E.coli" Bio/Technology I(5):396-397 (1983).
`Kohler, G., et al , "Immunoglobulin chain loss in hybridoma
`cell lines," Proc. Natl Acad. Sci., 77:2197-99 (1980).
`Kohler, G. BioScience Reports 5:533-549 (1985) (Plaintiff
`Exhibit 1108, Case No. CIV S-00-1252 WBS GGH).
`Krag et al., J. Biological Chemistry, vol. 257, No. 14, p.
`8424 (1983) (Exhibit 1115; Int. No. 104,532).
`Krag, J. Biol. Chem. 254:9167-9177 (1979) (Exhibit 1043;
`Int. No. 104,532).
`Krolick et al. 1982. In vivo therapy of a Murine B cell tumor
`(BCL I) using antibody—ricin a chain immunotoxins. J Exp.
`Med. 155:1797-1809 (Exhibit 2122; Int. No. 104,532).
`Kyle, "Classification and Diagnosis of Monoclonal Gammo-
`pathies," Chapter 16 (pp. 135-150) in Rose and Friedman,
`Manual of Clinical Immunology, Second Edition (1980).
`Levy, R. and R.A. Miller. 1983. Biological and clinical
`implications of lymphocyte hybridomas: tumor therapy with
`monoclonal antibodies. Ann. Rev. Med-34:107-116
`(Exhibit 2121; Int. No. 104,532).
`Lifely et al., Glycobiology, vol. 5 No. 8; 813-822, 1995
`(Exhibit 1170; Int. No. 104,532).
`Lingappa et al. 1980. Signal sequences for early events in
`protein secretion and membrane assembly. Ann. NYAcad.
`Sci. 343:356-61 (Exhibit 2147; Int. No. 104,532).
`Linscott's Directory (formerly Catalog) of Immunological
`and Biological Reagents, second edition 1982-83, pp. 1-57.
`LoBuglio and Saleh, Am. J. Medical Sciences, Sep. 1992
`vol. 304, No. 3, pp. 214-224 (Exhibit 1160; Int. No. 104,
`532).
`Liu et al., "Expression of mouse: human immunoglobulin
`heavy—chain cDNA in lymphoid cells" Gene 54(1):33-40
`(1987).
`M.D. Pegram et al., "Antibody dependent cell—mediated
`cytotoxicity in breast cancer patients in Phase III clinical
`trials of a humanized anti—HER2 antibody", Proc Am.
`Assoc. Cancer Res., 1997, 38:602 (#4044) (Exhibit 2248;
`Int. No. 104,532).
`
`Genzyme Ex. 1006, pg 104
`
`

`
`US 6,331,415 Cl
`Page 5
`
`Ma, S. and W. Nashabeh. 1999. Carbohydrate analysis of a
`chimeric recombinant monoclonal antibody by capillary
`electrophoresis with laser—induced fluorescence detection.
`Analytical Chemistry 71:5185-5192 (Exhibit 2145; Int. No.
`104,532).
`Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. Table of
`Contents; "Extraction, Purification, and Analysis of MRNA
`from Eukaryotic Cells", 187-209; "Synthesis and Cloning
`of CDNA", 211-246; and "Construction of Genomic Librar-
`ies", 269-307. In Molecular Cloning A Laboratory Manual,
`New York: Cold Spring Harbor Laboratory (Exhibit 2008;
`Int. No. 104,532).
`Margulies et al., "Regulation of immunoglobulin expression
`in mouse myeloma cells" Immunoglobulin Expression pp.
`781-791 (1977) (GNE—MED 31462).
`Marx, J. Science 229:455-456 (1985) (Plaintiff Exhibit No.
`1118, Case No. CIV S-00-1252 WBS GGH).
`Martinis et al., "Monoclonal antibodies with dual antigen
`specificity" Oncology pp. 311-316.
`Matsuuchi et al. 1981. An analysis of heavy chain glycopep-
`tides of hybridoma antibodies: correlation between antibody
`specificity and sialic acid content. Journal of Immunology
`127(5):2188-90 (Exhibit 2060; Int. No. 104,532).
`Mercola et al., "Transcriptional Enhancer Elements in the
`Mouse Immunoglobulin Heavy Chain Locus," Science, vol.
`221, No. 4611, p. 663-65 (Aug. 12, 1983).
`Meredith et al., J. Nucl. Med, Jan. 1992, 33:23-29 (pp.
`13-19).
`Meredith et al., J. Nucl. Med., vol. 33, No. 9: 1648-1653,
`Sep. 1992.
`Meredith, et al., Hum. Antibod. Hybridomas, 1993,
`4:190-197 (Exhibit 1083; Int. No. 104,532).
`Miles Biochemicals 1979-80, p. 140-142.
`Miller et al., "Transfection of human lymphoblastoid cells
`with herpes simplex viral DNA," Proc. Natl. Acad. Sci., vol.
`76, No. 2, pp. 949-953 (Feb. 1979).
`Morell et al. 1971. The role of sialic acid in determining the
`survival of glycoproteins in the circulation. J. Biol Chem.
`246:1461-1467 (Exhibit 2117; Int. No. 104,532).
`Morrison SL, et al., "A mouse myeloma variant with a defect
`in light chain synthesis," Eur. J. Immunol., 9:461-65 (1979).
`Morrison et al. 1988. Genetically engineered antibody mol-
`ecules: new tools for cancer therapy. Cancer Investigation
`6(2):185-92 (Exhibit 2085; Int. No. 104,532).
`Morrison et al. 1988. Production and characterization of
`genetically engineered antibody molecules. Clinical Chem-
`istry 34(9):1668-75 (Defendant Exhibit 5009, Case No. CIV
`S-00-1252 WBS GGH).
`Morrison, S. Hospital Practice 24(10):65-80 (1989)
`(GNE—MED 077476).
`Morrison, S., "In vitro antibodies: strategies for production
`and application" Annual Review of Immunology
`10:239-265 (1992).
`Mulligan, RC, et al., "Selection for animal cells that express
`the Escherichia colt gene coding for xanthine—guanine phos-
`phoribosyltransferase," Proc. Natl. Acad. Sci., 78 :2072-76
`(1980).
`Munro, "Uses of chimeric antibodies," Nature 312:597
`(1984).
`Neuberger, M. TIBS 347-349 (1985) (Plaintiff Exhibit 1130
`(Case No. CIV S-00-1252 WBS GGH).
`Neuhaus et al., JACC 14:1566-1569 (Nov. 15, 1989)
`(Exhibit 1032; Int. No. 104,532).
`
`Neumaier et al., Cancer Research 50:2128-2134 (Apr. 1,
`1990) (Exhibit 1013; Int. No. 104,532).
`Nose, M. and H. Wigzell. 1983. Biological significance of
`carbohydrate chains on monoclonal antibodies. Proc. Natl.
`Acad. Sci. USA 80:6632-6636 (Exhibit 2022; Int. No. 104,
`532).
`Oi et al , "Immunoglobulin Gene Expressin in Transformed
`Lymphoid Cells," Proc. Natl. Acad. Sci., vol. 80, No. 3, p.
`825-59 (Feb. 1, 1983).
`Oi & Morrison BioTechniques 4(3):214-221 (1986) (Plain-
`tiff Exhibit 1135, Case No. CIV S-00-1252 WBS GGH).
`Oldham, R. 1983. Monoclonal antibodies in cancer therapy.
`Journal of Clinical Oncology 1:582-590 (Exhibit 2119; Int.
`104,532).
`Orfila et al., "Immunofluorescence study of "non—idio-
`pathic" renal amyloidosis," Hum. Pathol. 14(4):362-7
`(1983).
`Peakman et al., Hum. Antibod. Hybridomas 5:65-74 (1994)
`(Exhibit 1038; Int. No. 104,532).
`Page et al., Biotech, 9:64-68 (1991).
`Picard et al., "Correct transcription of a cloned mouse
`immunoglobulin gene in vivo," Proc. Natl. Acad. Sci., vol.
`80, pp. 417-421 (Jan. 1983).
`Potamianos et al. 2000, Radioimmunoscintigraphy and
`Radioimmunotherapy in Cancer: Principles and Application,
`Anticancer Research 20, 925-948 (Exhibit 2185, Int. No.
`104,532).
`Primus et al., Cancer Immunol Immunotherapy (1990)
`31:349-357 (Exhibit 1164; Int. No. 104,532).
`Queen and Baltimore, "Immunoglobulin gene transcription
`is activated by downstream sequence elements" Cell
`33(3):741-748 (Jul. 1983).
`Queen, C, "Comparison of mouse and human V—kappa
`domains" (Submitted by PDL Mar. 27, 1997).
`Queen, C., "Comparison of human and mouse VH domains"
`(Submitted by PDL on Mar. 27, 1997.
`Rademacher et al. (1988) Ann. Rev. Biochem. 57:785-838
`(Exhibit 2165; Int. No. 104,532).
`Raju et al. 2000. Species—specific variation in glycosylation
`of IgG: evidence for the species—specific sialylation and
`branch—specific galactosylation and importance for engi-
`neering recombinant glycoprotein therapeutics. Glycobiol-
`ogy 10(5):477-486 (Exhibit 2027; Int. No. 104,532).
`Reff et al., Blood, vol. 83, No. 2, pp. 435-445 (1994)
`(Exhibit 1111; Int. No. 104,532).
`Renner et al. 1997. Monoclonal antibodies in the treatment
`of non—Hodgkin's lymphoma: recent results and future pros-
`pects. Leukemia 11(2):555-559 (Exhibit 2019; Int. No. 104,
`532).
`Rhodes and Birch Biotechnology 6:518, 521, 523 (1988)
`(Exhibit 1046; Int. No. 104,532).
`Rhodes, Adv. Anim Cell. Biol. Technol. Bioprocess.,
`472-74 (1988) (Exhibit 1045; Int. No. 104,532).
`Riechmann et al. 1988. Expression of an antibody Fv frag-
`ment in myeloma cells. Journal of Molecular Biology
`203(3):825-8 (Exhibit 2087; Int. No. 104,532).
`Riechmann et al. 1988. Reshaping human antibodies for
`therapy. Nature 322:323-327 (Exhibit 1022; Int. No. 104,
`532).
`Rosen et al. 1983. Application of monoclonal antibodies to
`tumor diagnosis and therapy. Annals of Clinical and Labora-
`tory Science 13:173-184 (Exhibit 2120; Int. No. 104,532).
`Routledge et al., Eur. J. Immunol. 1991, 21:2717-2725
`(Exhibit 1068; Int. No. 104,532).
`
`Genzyme Ex. 1006, pg 105
`
`

`
`US 6,331,415 Cl
`Page 6
`
`Tomimo et al., "Specificity of eluted antibody from renal
`tissues of patients with IgA nephropathy," Am. J. Kidney
`Dis. 1(5):276-80 (1982).
`
`COS and CHO cells. Current Opinion in Biotechnology 6:
`553-560 (Exhibit 2108; Int. No. 104,532).
`
`oligosaccharide chains on immunological activites of human
`IgG. Journal of Hematology 16:285-90 (Exhibit 2092; Int.
`No. 104,532).
`
`hamster cell mutants deficient in dihydrofolate reductase
`activity. Proc. Natl. Acad Sci. USA 77:4216-4220 (Exhibit
`2031; Int. No. 104,532).
`
`104,532).
`Van Nagell et al. 1980. Radioimmunodetection of primary
`and metastasis ovarian cancer using radiolabeled antibodies
`to carcinoembryonic antigen. Cancer Research 40(3):502-6
`(Exhibit 2043; Int. No. 104,532).
`Verhoeyen et al. 1988. Reshaping human antibodies: graft-
`
`(Exhibit 2089; Int. No. 104,532).
`Villiers et al. "Transcriptional 'enhancers' from SV40 and
`
`Res., vol. 10, No. 24, p. 7965-76 (1982).
`
`(GNE—MED-01597).
`
`monoclonal antibody against alpha (1 6) dextran increases
`its affinity for antigen. Journal Of Experimental Medicine
`168(3):1099-109 (Exhibit 2090; Int. No. 104,532).
`Weidle et al. 1987. Expression of antibody CDNA in murine
`myeloma cells: possible involvement of additional regula-
`tory elements in transcription of in immunoglobulin genes.
`Gene 60 (2-3):205-216 (Exhibit 2082; Int. No. 104,532).
`
`antibody directed against creatine kinase from separately
`expressed heavy and light chains in non—lymphoid cells.
`Gene 51(I):21-9 (Exhibit 2081; Int. No. 104,532).
`White et al., "Biologicals from recombinant microorganisms
`and animal cells: production and recovery," Proceedings of
`the 34th [i.e. 35th] OHOLO Conference, Eilat, Isreal, 1990,
`p. 567, White et al. (Ed.) (Exhibit 1073; Int. No. 104,532).
`Whittle et al., Expression in COS cells of a mouse
`human
`chimaeric B72.3 antibody, 1987, pp. 499-505, vol. 1, No. 6.
`Wickens et al. 1978. Synthesis of double—stranded DNA
`complementary to lysozyme, ovomucoid, and ovalbumin
`mRNAs. Optimization of full length second strand synthesis
`by Escherichia colt DNA polymerase 1. Journal ofbiological
`
`104,532).
`Williams et al. Cancer Research (Suppl.) 50:1029s-1030s
`(Feb. 1, 1990) (Exhibit 1012; Int. No. 104,532).
`
`13—globin gene in mouse fibroblasts," Proc. Natl. Acad. Sci.,
`Bol. 76, No. 11 pp. 5694-88 (Nov. 1979).
`Wood et al., J. Immunol., vol. 145:3011-3016, No. 9, Nov.
`1, 1990 (Exhibit 1089; Int. No. 104,532).
`
`Schein et al., "Formation of Soluble Recombinant Proteins
`in Escherichia colt is Favored by Lower Growth Tempera-
`ture" BioTechnoloqy 6:291-294 (1988).
`Schein, Catherine H., "Production of soluble recombinant
`proteins in bacteria" Bio/Technology 7:1141-1149 (1989).
`
`(Exhibit 1056; Int. No. 104,532).
`Sheeley et al., Analytical Biochemistry 247, 102-110 (1997)
`(Exhibit 1096; Int. No. 104,532).
`Sidman, C. 1981. Differing requirements for glycosylation
`in the secretion of related glycoproteins is determined nei-
`
`oligosaccharide
`256(18):9374-9376 (Exhibit 2100; Int. No. 104,532).
`
`I(
`
`1976).
`Southern, PJ et al. "Transformation of mammalian cells to
`antibiotic resistance with a bacterial gene under control of
`the SV40 early region promoter," J. Molec. AppL Genet.,
`1:327-41 (1982).
`
`(Exhibit 1151; Int. No. 104,532).
`Stafford and Queen, "Cell—type specific expression of a
`
`77-79 (Nov. 3, 1983).
`Stevenson et al., 1989, A Chimeric Antibody With Dual Fc
`Regions (bisFabFc) Prepared by Manipulations at the IgG
`Hinge, Anti—Cancer Drug Design 3, 219-230 (Exhibit 2182;
`Int. No. 104,532).
`
`(Exhibit 1026; Int. No. 104,532).
`Summers et al., "Stable expression in mouse cells of nuclear
`neoantigen after transfer of a 3.4—megadalton cloned frag-
`ment of Epstein—Barr virus DNA," Proc. Natl. Acad. Sci.,
`vol. 79, pp. 5688-5692 (Sep. 1982).
`
`regions and mouse variable regions directed against carcino-
`
`84(I):214-8 (Exhibit 2080; Int. No. 104,532).
`T.E. Hotaling et al., "The humanized anti—HER2 antibody
`rhuMAb HER2 mediates antibody dependent cell—mediated
`cytotoxicity via FcyR III", Proc. Am. Assoc. Cancer Res.,
`1996, 37:471 (#3215).
`Takeda et al. Nature 314:452-454 (1985) (Plaintiff Exhibit
`1171, Case No. CIV S-00-1252 WBS GGH).
`Takei et al. 1980. Monoclonal antibody H9/25 reacts with
`functional subsets of T and B cells: killer, killer percursor
`and plaque—forming cells. European Journal of Immunology
`10(7):503-9 (Exhibit 2042; Int. No. 104,532).
`
`1152; Int. No. 104,532).
`Tan et al. 1985. A human—mouse chimeric in immunoglobu-
`lin gene with a human variable region is expressed in mouse
`
`(Exhibit 2078; Int. No. 104,532).
`Taniguchi et al., "Expression of the Human Fibroblast Inter-
`Escherichia Colt",
`USA, 77(9):5230-5233 (Sep. 1980).
`Tarentino et al. 1974. The release of intact oligosaccharides
`from specific glycoproteins by Endo—o—N—acetylglu-
`
`249:818-824 (Exhibit 2116; Int. No. 104,532).
`
`Genzyme Ex. 1006, pg 106
`
`

`
`US 6,331,415 Cl
`Page 7
`
`CH2-associated Carbohydrate Structure on the Functional
`
`Immunoglobulin GI, J. Exp. Med 180,1087-1096 (Exhibit
`2186; Int. No. 104,532).
`
`human antithrombin III in Chinese hamster ovary cells. Biol
`Technology 5:720-5 (Exhibit 1076; Int. No. 104,532).
`
`0543-0544).
`Mumford Nbk #1246 (Bates Nos. 0615, 0617, 0626-0627,
`0645).
`
`0187-0188,
`0244-0261, 0304-0307).
`Wetzel Nbk #1432 (Bates Nos. 0034 0044, 0047, 0049 0050,
`0053, 0061 0064, 0077 0081, 0087-0088).
`
`0858).
`
`0885-0887, 0889).
`
`0950, 0954-0957).
`Perry Nbk #1683 (Bates Nos. 0336-0342, 0357-0362).
`File History U.S. Appl. No. 08/909,611.
`File History of U.S. Patent No. 5,545,404 (U.S. Appl. No.
`08/335,400) (Exhibit 2163; Int. No. 104,532).
`File History of U.S. Patent No. 5,545,405 (U.S. Appl. No.
`08/335,401) (Exhibit 2164; Int. No. 104,532).
`Robinson's U.S. Appl. No. 07/016,202, filed Jan. 8, 1987
`(Exhibit 2153; Int. No. 104,532).
`Robinson's U.S. Appl. No. 08/471,984, filed Jun. 6, 1995
`(Exhibit 2154; Int. No. 104,532).
`Cabilly U.S. Appl. No. 07/205,419, filed Jun. 10, 1988.
`Restriction Requirement (Paper No. 4) dated Mar. 6, 1990 in
`U.S. Appl. No. 07/205,419.
`Restriction Requirement (Paper No. 11) dated Sep. 7, 1990
`in U.S. Appl. No. 07/205,419.
`Appointment of Associate Attorney, Mar. 25, 1991 in U.S.
`Appl. No. 07/205,419.
`
`07/205,419.
`Amendment After Interference (Paper No. 24) filed Oct. 4,
`2001 in U.S. Appl. No. 07/205,419.
`Decision Granting Petition to Correct the Assignee on the
`Correction Page of U.S. Appl. No. 07/205,419, May 7, 2002.
`File History of U.S. Patent No. 4,816,397 (Boss et al.).
`
`572).
`Summary of Times Running, Feb. 28, 1991 (Int. No. 102,
`572).
`Designation of Lead Attorney (Cabilly), Mar. 14, 1991 (Int.
`No. 102,572).
`Submission of Associate Attorneys, Apr. 8, 1991 (Int. No.
`102,572).
`Revocation of Power of Attorney, Apr. 15, 1991 (Int. No.
`102,572).
`Boss et al. Substitution of Lead Attorney, Apr. 19, 1991 (Int.
`No. 102,572).
`Associate Power of Attorney, Apr. 19, 1991 (Int. No. 102,
`572).
`
`Cabilly et al. Motion for Extension of Time, May 28, 1991
`(Int. No. 102,572).
`
`(Int. No. 102,572).
`
`Notice to Opposing Party, Jun. 4, 1991 (Int. No. 102,572).
`Boss et al. Motion for Benefit of its PCT Application (Boss
`Motion 1), Jun. 4, 1991 (Int. No. 102,572).
`
`(Boss Motion 2), J